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The clinical and polysomnographic features in complex
sleep apnea syndrome
Handan İNÖNÜ1,*, Tansu ULUKAVAK ÇİFTÇİ2, Oğuz KÖKTÜRK2

Aim: Complex sleep apnea syndrome (CompSAS) is characterized by the onset of central apneas or a Cheyne-Stokes
breathing pattern in some patients with obstructive sleep apnea syndrome (OSAS) who were treated with continuous
positive airway pressure (CPAP). The etiology of CompSAS is unclear, but derangement of respiratory control has been
proposed. We sought to compare clinical and polysomnography (PSG) features of patients with CompSAS and OSAS.
Materials and methods: Records of PSG were evaluated in a total of 270 patients, retrospectively. CPAP titration was
prescribed in patients with an apnea-hypopnea index (AHI) of ≥15. Patients who developed a central AHI of ≥5 following
titration PSG were diagnosed with CompSAS.
Results: There were 71 patients with OSAS and 12 with CompSAS. The mean ages and body mass indexes (BMIs) were
similar between the 2 groups. The incidences of diagnostic AHI, congestive heart failure (CHF), and chronic renal failure
(CRF) were higher in patients with CompSAS. The average and minimum oxygen saturation levels were lower in patients
with CompSAS and those with diagnostic PSGs.
Conclusion: According to our results, lower oxygen saturation may cause instability of respiratory control in these
patients and may be responsible for the pathophysiology of CompSAS.
Key words: Central sleep apnea, Cheyne-Stokes breathing, complex sleep apnea syndrome, continuous positive airway
pressure, obstructive sleep apnea, congestive heart failure

Kompleks uyku apne sendromunun klinik ve polisomnografik özellikleri
Amaç: Kompleks Uyku Apne Sendromu (CompSAS) sürekli pozitif havayolu basınç (CPAP) tedavisi alan obstrüktif
uyku apne sendromlu (OSAS) bazı hastalarda, CPAP sonrası santral apnelerin veya Cheyne-Stokes solunum paterninin
meydana gelmesi ile karakterizedir. Hastalığın nedenleri tam bilinmemektedir, solunum kontrol mekanizmalarındaki
bozukluğun sorumlu olduğu ileri sürülmektedir. Bu çalışmada amacımız OSAS ve CompSAS’lı olguların klinik ve
polisomnografik özelliklerinin karşılaştırılmasıdır.
Yöntem ve gereç: Toplam 270 olgunun polisomnografi kayıtları retrospektif olarak değerlendirildi. Apne Hipopne
İndeksi (AHİ) ≥15 olan olgulara CPAP titrasyonu uygulandı. Titrasyon polisomnografisinde (PSG) santral AHİ ≥5 olan
olgular CompSAS kabul edildi.
Bulgular: OSAS’lı 71 olgu, CompSAS’lı 12 olgu mevcuttu. Yaş ortalaması ve beden kitle indeksi gruplar arasında
benzerdi. Tanısal AHİ, konjestif kalp yetmezliği, kronik böbrek yetmezliği insidansı CompSAS’lı grupta daha yüksekti.
Tanısal polisomnografik değerlendirmede ortalama ve minimum oksijen saturasyon düzeyleri CompSAS grubunda
anlamlı düzeyde düşüktü.
Sonuç: Sonuçlarımıza göre düşük oksijen saturasyon değerlerinin, CompSAS’lı hastalarda solunum kontrolünde
bozukluğa yol açabileceği ve bunun da patofizyolojide rol oynayabileceği düşünülmüştür.
Anahtar sözcükler: Santral uyku apne, Cheyne-Stokes solunumu, kompleks uyku apne sendromu, sürekli pozitif
havayolu basıncı, obstrüktif uyku apne, konjestif kalp yetmezliği
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Introduction
Obstructive sleep apnea syndrome (OSAS)
encompasses the majority of sleep related breathing
disorders. This syndrome is a commonly seen
disorder, affecting 4% of men and 2% of women (1).
The disorder is characterized by periods of breathing
cessation (apnea) and periods of reduced breathing
(hypopnea) during sleep (2). Although central sleep
apnea (CSA) is more frequently seen in some clinical
settings such as congestive heart failure (CHF) and
chronic renal failure (CRF), CSA is found in less than
5% of patients who have been admitted to sleep
disorder centers (3). A new category of sleepdisordered breathing has recently emerged. Some
patients with OSAS develop problematic central
apneas or a Cheyne-Stokes pattern with acute
application of continuous positive airway pressure
(CPAP), herein called complex sleep apnea syndrome
(CompSAS) (4-7). CompSAS is a different form of
sleep apnea. Clinical features of patients with
CompSAS are similar to those of OSAS, while the
breathing patterns resemble those of CSA.
Morgenthaler et al. estimated that the prevalence of
CompSAS would be 15% while the incidences of CSA
and OSAS were 0.4% and 84%, respectively (6). In
cases of CompSAS, CPAP suppresses obstructive
apneas, but apnea hypopnea index (AHI) is higher
due to central apneas, which is called residual AHI.
In this study, we aimed to assess the prevalence of
CompSAS
and
compare
clinical
and
polysomnographic features of patients with
CompSAS and OSAS.
Materials and methods
We performed a retrospective review of patients in
our sleep disorders center (Gazi University, Faculty of
Medicine, Ankara, Turkey). OSAS patients had been
examined by using polysomnography (PSG). An AHI
of ≥ 5/h was accepted as an inclusion criterion for this
sleep study. In this study, polysomnographic and
clinical records were evaluated in a total of 270
patients. All patients underwent PSG for suspected
OSAS. CPAP titration was prescribed for patients with
AHI of ≥15. CPAP titration was performed using an
automated CPAP device. The lower and the upper
limit of pressure provided by the device were set at 4
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cmH2O, and 20 cmH2O, respectively. Only 83 patients
underwent CPAP titration. Patients who had a central
AHI of ≥5 following titration PSG were diagnosed
with CompSAS. Patient characteristics, including age,
gender, body mass index (BMI), and concomitant
diseases, were recorded. Comorbidity data were either
obtained from the case notes or reported by patients
at the time of the sleep study.
Sleep Study
Overnight PSG was performed in all patients by
using a computerized system (Somnostar alpha;
Sensormedics, USA), which included the following
examinations: electrooculography (2 channels),
electroencephalography (4 channels), electromyogram of submental muscles (2 channels),
electromyogram of the anterior tibialis muscle of both
legs (2 channels), an electrocardiogram, and
airflowmeter (with an oro-nasal transducer). Chest
and abdominal efforts (2 channels) were recorded
using inductive plethysmography and arterial
oxyhemoglobin saturation (SaO2: 1 channel) by pulse
oximetry with a finger probe. Sleep stages were scored
according to the standard criteria of Rechtschaffen
and Kales (8). Arousals were scored according to the
accepted criteria of the American Sleep Disorders
Association (ASDA) (9). In our study, we assessed
nasal airflow with a pressure transducer. Based on the
ASDA criteria for measurements, definitions, and
severity ratings established for the Sleep Related
Breathing Disorders Task Force Report (2), apnea is
defined as the cessation of airflow for ≥10 s and
hypopnea as a recognizable, transient reduction, but
not a complete cessation of breathing for ≥10 s . A
>50% decrease in the amplitude of a validated
measure of breathing or a reduction of <50% in the
amplitude associated with either an oxygen
desaturation of ≥3% or an arousal should be present.
Obstructive apneas and hypopneas are typically
distinguished from central apneas-hypopneas by the
detection of respiratory efforts during the episode.
AHI was defined as the number of apneas and
hypopneas per hour of sleep. Patients with an AHI of
≥5 were considered to have OSAS; patients who
developed a central AHI of ≥5 titration PSG were
diagnosed with CompSAS. All subjects underwent
all-night PSG. Apart from OSAS patients with upper
airway resistance syndrome (UARS), central sleep
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apnea syndrome (CSAS), narcolepsy, and those
having other factors that could promote the
occurrence of central sleep apnea as sleep instability,
periodic limb movements (PLMs) and drugs were
excluded from the study.
Statistical analysis
CompSAS and OSAS groups were compared in
terms of demographic variables, concomitant
diseases, and characteristics of diagnostic and
titration PSG. The significance of differences within
groups was analyzed by using Student’s t test and
categorical data with chi-square (χ2) and Fisher’s exact
probability test. Arithmetic means and standard
deviation (x ± SD) were calculated for all values.
All statistical analyses were carried out by using
statistical software (SPSS, version 11.0 for Windows;
SPSS, Chicago, IL, USA). Differences were considered
significant at P < 0.05.
Results
A total of 270 patients’ records were evaluated. Of
the 83 patients who had a CPAP titration study
performed with OSAS, 12 (14.4%) had a central AHI
of ≥5. The demographic and clinical data of patients
with CompSAS and OSAS are presented in Table 1.
The distribution of mean ages, BMIs, and genders of
patients were similar between the groups (P values of
0.155, 0.405, and 0.758, respectively). CompSAS
patients were less prone to somnolence than patients
with OSAS (Epworth Sleepiness Score 8.09 ± 5.3 in
CompSAS vs. 11.7 ± 5.3 in OSAS, P = 0.041).

The findings of the diagnostic PSG are shown in
Table 2. The average AHI in both groups was within
the severe range of OSAS, but patients with CompSAS
had more severe sleep-disordered breathing (37.7 ±
32.3 and 57.1 ± 35.2, respectively), and the difference
was statistically significant (P = 0.026). There was no
difference between the 2 groups with regard to
percentage ratio of non-rapid eye movement (NREM)
and rapid eye movement (REM) sleep stages, sleep
efficiency, and arousal index (ARI). Awake oxygen
saturation (SpO2) was similar between the 2 groups;
however, the average SpO2 and minimum SpO2 were
lower in patients with CompSAS than in patients with
OSAS (87.1 ± 4.2 vs. 89.3 ± 4.6 and 68.9 ± 11.3 vs. 76.2
± 9.9, respectively) and there were statistically
significant differences between them (P = 0.027 and P
= 0.017, respectively). In the CompSAS group,
significantly more severe oxygen desaturation (SpO2 <
90%) was seen during the night when compared with
the OSAS group (60.05 ± 37.8 vs. 38.5 ± 35.2, P =
0.042). In the CompSAS group, central (0.82 ± 1.35
vs. 0.22 ± 1.12, P < 0.001), obstructive (26.2 ± 18.5 vs.
21.7 ± 19.3, P = 0.019), and mixed apnea index (8.3 ±
11.9 vs. 5.2 ± 9.2, P < 0.001) were significantly higher
when compared with the OSAS group.
The findings of titration PSG are shown in Table 3.
CPAP suppressed obstructive apneas, but residual
AHI, mostly from central apneas, remained higher in
patients with CompSAS (9.8 ± 5.8 vs. 3.1 ± 4.7 in
OSAS, P < 0.001). Central apneas were much more
frequently seen in patients with CompSAS (27.3 ±
18.7 in CompSAS, 2.4 ± 2.6 in OSAS, P < 0.001).
Similarly, the duration of central apneas was longer in

Table 1. Demographic and clinical data of patients with CompSAS and OSAS.

Characteristics

CompSAS
(n = 12)

OSAS
(n = 71)

P-value

55.8 ± 10.6*

51.2 ± 10.2

0.155

69.2

72.5

0.758

BMI (kg/m2) (n ± SD)

31.5 ± 6.2

30 ± 5.5

0.405

ESS (n ± SD)

8.09 ± 5.3

11.7 ± 5.3

0.041

Mean age (year) (n ± SD)
Sex (male) (%)

BMI=body mass index , ESS=Epworth sleepiness score
* Mean ± standard deviation
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Table 2. Diagnostic polysomnographic findings.
Variables

CompSAS
(n = 12)

OSAS
(n = 71)

P-value

Stage 1 (%)

18.9 ± 9.7

14.9 ± 11.1

0.064

Stage 2 (%)

50.6 ± 8.3

48 ± 9.1

0.262

Stage 3 (%)

4.6 ± 3.1

6.1 ± 4

0.135

Stage 4 (%)

8.1 ± 7.9

10.3 ± 6.9

0.226

REM (%)

17.5 ± 5.6

20.6 ± 7.4

0.120

Sleep efficiency (%)

71.3 ± 17.6

74.3 ± 13.3

0.604

ARI events/h

25.6 ± 16.8

21.9 ± 18.7

0.224

AHI events/h

57.1 ± 35.2

37.7 ± 32.3

0.026

Awake O2 sat (%)

94.1 ± 2.08

94.8 ± 1.5

0.297

Average O2 sat (%)

87.1 ± 4.2

89.3 ± 4.6

0.027

Minimum O2 sat (%)

68.9 ± 11.3

76.2 ± 9.9

0.017

Desaturation (%)*

60.05 ± 37.8

38.5 ± 35.2

0.042

CAI, events/h

0.82 ± 1.35

0.22 ± 1.12

< 0.001

OAI, events/h

26.2 ± 18.5

21.7 ± 19.3

0.019

MAI, events/h

8.3 ± 11.9

5.2 ± 9.2

< 0.001

REM=rapid eye movement sleep, ARI=arousal index, AHI=apnea hpopnea index, sat= saturation,
* Sleep time of SpO2 < 90%, CAI= central apnea index, OAI= obstructive apnea index, MAI= mixed apnea index, sleep stages are given
as % of total sleep time

patients with CompSAS (15.5 ± 1.8 vs. 9.3 ± 6.8, P <
0.001). CPAP titration was prescribed for 83 cases;
there were no differences in the requirements for
CPAP pressures between CompSAS and OSAS (8.4 ±
1.4 and 8.8 ± 1.5, respectively, P = 0.380).
When CompSAS and OSAS patients were
compared in terms of concomitant diseases, the
difference was significant as for CHF and CRF ratio

(16.6% in CompSAS, 2.43% in OSAS for CHF, P =
0.048 and 8.3% in CompSAS, 0% in OSAS for CRF, P
= 0.047) (Table 4).
Discussion
CompSAS is a distinct clinical entity different from
OSAS. Though accepted as a speculative claim, this

Table 3. Titration polysomnographic findings.
Variables

Residual AHI

CompSAS
(n = 12)

OSAS
(n = 71)

P-value

9.8 ± 5.8

3.1 ± 4.7

<0.001

Number of cases with CA (n ± SD)

27.3 ± 18.7

2.4 ± 2.6

<0.001

Duration of CA (s)

15.5 ± 1.8

9.3 ± 6.8

<0.001

CPAP pressure (cmH2O)

8.4 ± 1.4

8.8 ± 1.5

0.380

CA=Central apnea
CPAP = Continuous Positive Airway Pressure
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Table 4. The incidences of concomitant diseases in patients with CompSAS and OSAS.

Incidences (%)

CHF

CompSAS
(n = 12)

OSAS
(n = 71)

P-value

16.6

2.4

0.048

CRF

8.3

0

0.047

HT

58.3

44.5

0.386

CAD

16.6

13.4

0.670

CVD

0

0.4

1.000

CHF=congestive heart failure, CRF=chronic renal failure, HT= hypertension, CAD=coronary artery disease, CVD=cerebrovascular
disease

syndrome has been attempted to be explained by
some physiologic mechanisms (10). Two mechanisms
are mostly emphasized. One of them is hypocapnia,
and resultant central apneas, the other, is impaired
respiratory control occurring as a result of increased
chemosensitivity of the respiratory center. In
respiratory control, chemoreceptor inputs play key
roles. Hypercapnia and hypoxemia are the most
important stimulators of the respiratory center. The
response of the respiratory center to oxygen (O2) and
carbon dioxide (CO2) is different. In other words,
chemosensitivity differs from person to person.
Higher chemosensitivity leads to impairment of
respiratory stability. Very small scale variations in
chemical stimuli in these individuals induce
exaggerated responses. For example, in patients with
a higher chemosensitivity, even milder increases in
CO2 or minor decreases in O2 levels lead to enhanced
respiratory response and impaired respiratory control
(3). In the presence of a highly responsive
chemoreceptor, arterial CO2 (PaCO2) decreases below
apneic levels (i.e. below the hypocapnia-induced
apneic threshold) and apnea occurs. Sleep unmasks a
highly sensitive hypocapnia-induced apneic threshold
(11). In patients with OSAS, variations in blood gas
concentrations (especially hypoxia) because of
recurrent nocturnal apneas increase chemoreceptor
sensitivity with a resultant higher ventilatory response
(12). In patients with complex sleep apnea syndrome,
deranged cardiovascular stability has been reported
(5). In cardiac failure patients with central apneas, it
has been demonstrated that oxygen therapy corrected
desaturation and decreased the number of nocturnal

sympathetic discharges and central apneas (13).
Consequently, oxygen level plays an important role in
respiratory and cardiovascular control and hypoxia
offsets this regulation mechanism. In our study, the
average SpO2 and minimum SpO2 values were lower
in patients with CompSAS when compared with
patients with OSAS and also oxygen desaturation was
more severe in the CompSAS group than in the OSAS
group. Based on the information in our study, it has
been suggested that hypoxia might be one of the
pathophysiological mechanisms playing a role in the
development of CompSAS.
Furthermore, reflex inhibition might play a role in
the central control of respiration. Some inhibitor
signals originating from the upper respiratory tract
have a role in the pathogenesis of central apnea (5,11).
Stability of breathing in individuals with low
threshold for arousal is also disturbed. Arousal gives
rise to hyperventilation and PCO2 below the apneic
threshold results in central apnea. The breathing
process has a stable course during slow wave sleep
stages due to the elevation of the arousal threshold.
This mechanism may explain why central respiratory
events tend to occur during lighter stages of sleep.
In this retrospective study, the prevalence of
CompSAS was 14.4%, which is consistent with the
only reported prevalence of 15% in the literature (6).
Morgenthaler et al. showed that patients with
CompSAS had a lower diagnostic AHI in CSA, but it
was higher in patients with OSAS (6). Our results
revealed that patients with CompSAS had more severe
697
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sleep-disordered breathing than patients with OSAS.
As seen in Table 2 in the CompSAS group, central
and mixed apnea index were significantly higher
when compared with the OSAS group, in diagnostic
PSG. Post-titration residual apneas in the CompSAS
group might be these baseline central and mixed
apneas. Even if AHI was higher and oxygen
saturations were lower in the CompSAS group,
Epworth scores were found to be significantly lower.
In other words, somnolence was lower in this group.
These data were in contrast to the expected findings.
The majority of patients with CompSAS are male.
It has been shown that males have a higher incidence
of disrupted and lighter sleep than females. This
mechanism may explain why CompSAS is more
frequently seen in the male population. It is reported
that BMI is lower in CompSAS cases than in OSAS
cases (5). In our study, no possible difference between
OSAS and CompSAS groups as for gender and BMI
was found because of the scarcity of cases.
Lehman et al. reported that a history of ischemic
heart disease or heart failure was more prevalent
amongst patients with CSA (14). In our study, when
the incidences of CHF and CRF were compared in
both groups, in the CompSAS group higher
incidences of these diseases were found (16.6% vs.
2.4%, P = 0.048 for CHF, 8.3% vs. 0%, P = 0.047 for
CRF). Because of the scarce number of cases in this
group, the clinical significance of these data may be
debatable.
There is a controversy regarding the optimal
treatment of CompSAS. However, adaptive servo
ventilation (ASV) is the most popular and
emphasized method in the treatment of CompSAS. In
the literature, numerous publications have indicated
that central apneas and Cheyne-Stokes syndrome
could be improved with CPAP therapy (15), while
others have suggested that CPAP therapy had no
effect on central apneas or, on the contrary, it even
worsened this condition (16). In a study, the outcomes
of long-term (49-452 days, median: 195 days) CPAP
treatment of 13 patients with CompSAS were
evaluated and 7 patients with AHIs <10 and 6 patients
with AHIs >10 were observed. The study suggested
that 50% of the cases responded to CPAP (4).
Moreover, other studies were carried out to compare
the effects of noninvasive positive pressure ventilation
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(NPPV) and ASV with those of CPAP in CompSAS
and they demonstrated that NPPV and ASV had
improved AHI and ARI more than CPAP, but the
effect of ASV was superior to that of NPPV (17).
Another study showed that sleep-related breathing
problems in patients with CSA, CSA/Cheyne-Stokes
respiration (CSR) and CompSAS could not easily be
controlled with CPAP. In the cases in which the
method of ASV was used, a dramatic improvement in
sleep-disordered breathing and sleep architecture was
observed (18). In addition to CPAP, various
therapeutic options have been studied including
oxygen
supplementation,
pharmacotherapy
(theophylline, acetazolamide), and minimizing
hypocapnia by using a nonvented mask, usage of the
lowest pressure, enhanced expiratory rebreathing
space, and controlled increases in CO2 concentrations
in the inhaled air (11,19). For all of our patients, CPAP
was prescribed. There were no differences in the
requirements for CPAP pressures between the 2
groups. Subjective improvement was evaluated by
telephone questioning. All of the patients reported
improvement in sleep quality and/or daytime
sleepiness. When the response to CPAP therapy was
evaluated, in cases with mostly mixed apneas the
response to treatment was apparently inadequate (11).
In our results, when diagnostic PSG registries of our
cases were analyzed, the number of mixed apneas was
less than the number of obstructive apneas. This fact
could be accounted for the improved response of our
cases to CPAP therapy. We later obtained objective
follow-up data to define treatment responses more
efficiently. Recently one of the mechanisms proposed
for the treatment response has been that in most
patients with CompSAS with long-term CPAP
treatment the response of the respiratory center to
chemical stimuli is reset, leading to normalization of
the respiratory pattern, and resolution of central
apneas (12).
Conclusion
The results of our study revealed that the rate of
CHF was significantly higher, the average and
minimum values of oxygen saturation were lower, and
more severe oxygen desaturation was observed in the
diagnostic PSG group with CompSAS. Disturbances
in the mechanisms of respiratory and/or
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cardiovascular control may be responsible for the
pathophysiology of CompSAS according to our
results. Further research is needed to understand its
pathophysiology in detail. Identifying the clinical

profile of patients with CompSAS might be helpful in
understanding the pathophysiology of this syndrome
and in discovering management strategies.
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